• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.

作者信息

Pajusola K, Aprelikova O, Armstrong E, Morris S, Alitalo K

机构信息

Department of Pathology, University of Helsinki, Finland.

出版信息

Oncogene. 1993 Nov;8(11):2931-7.

PMID:7692369
Abstract

FLT4 is a recently cloned gene encoding a transmembrane tyrosine kinase related to the FLT1 and KDR/FLK1 vascular endothelial growth factor receptors. We have previously shown that FLT4 is expressed as transcripts of 4.5 and 5.8 kb in several human fetal and adult tissues. Here we show that these transcripts encode two polypeptides, FLT4s (short) and FLT41 (long), which are proteolytically processed in transfected cells and leukemia cells and which have different carboxy terminal tails. The 3' coding region of the 5.8 kb mRNA was found to be 65 codons longer than that of the the 4.5 kb mRNA. Analysis of the genomic structure of the region encoding the two carboxy termini revealed that the two transcripts are generated by alternative polyadenylation and subsequent alternative splicing during RNA processing. Our findings thus show regulation of FLT4 structure in the carboxy terminal tail considered important for receptor function. The significance of the two forms may relate to the role of additional potential autophosphorylation sites in the FLT4 long form.

摘要

相似文献

1
Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.
Oncogene. 1993 Nov;8(11):2931-7.
2
Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase.
Oncogene. 1995 Mar 2;10(5):973-84.
3
Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors.FLT4的信号传导特性,一种与两种血管内皮生长因子受体相关的经蛋白水解加工的受体酪氨酸激酶。
Oncogene. 1994 Dec;9(12):3545-55.
4
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.一种新型血管内皮生长因子VEGF-C,是Flt4(血管内皮生长因子受体-3)和KDR(血管内皮生长因子受体-2)受体酪氨酸激酶的配体。
EMBO J. 1996 Jan 15;15(2):290-98.
5
Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.
Oncogene. 1995 Sep 7;11(5):921-31.
6
FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.
Cancer Res. 1992 Oct 15;52(20):5738-43.
7
The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.FLT4基因编码一种与血管内皮生长因子受体相关的跨膜酪氨酸激酶。
Oncogene. 1993 May;8(5):1233-40.
8
Alternative splicing of the human VEGFGR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus.人类内源性逆转录病毒整合导致人VEGFGR-3/FLT4基因的可变剪接
J Mol Evol. 2001 Aug;53(2):77-9. doi: 10.1007/s002390010195.
9
Characterization of murine Flt4 ligand/VEGF-C.小鼠Flt4配体/VEGF-C的特性分析
Oncogene. 1997 Jul 31;15(5):613-8. doi: 10.1038/sj.onc.1201191.
10
HERV-K-T47D-Related long terminal repeats mediate polyadenylation of cellular transcripts.与HERV-K-T47D相关的长末端重复序列介导细胞转录本的聚腺苷酸化。
Genomics. 2000 May 15;66(1):98-103. doi: 10.1006/geno.2000.6175.

引用本文的文献

1
Regulation of VEGFR3 signaling in lymphatic endothelial cells.淋巴管内皮细胞中VEGFR3信号通路的调控
Front Cell Dev Biol. 2025 Feb 13;13:1527971. doi: 10.3389/fcell.2025.1527971. eCollection 2025.
2
Bioactive VEGF-C from E. coli.大肠杆菌来源的生物活性 VEGF-C。
Sci Rep. 2022 Oct 28;12(1):18157. doi: 10.1038/s41598-022-22960-0.
3
Genetic Variants of and Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib.和 的遗传变异是索拉非尼治疗的肾细胞癌患者生存的决定因素。
Cancer Res. 2019 Jan 1;79(1):231-241. doi: 10.1158/0008-5472.CAN-18-1089. Epub 2018 Nov 1.
4
Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels.血管内皮生长因子C在淋巴管形态发生中的生物学特性
Front Bioeng Biotechnol. 2018 Feb 12;6:7. doi: 10.3389/fbioe.2018.00007. eCollection 2018.
5
The optimum marker for the detection of lymphatic vessels.用于检测淋巴管的最佳标志物。
Mol Clin Oncol. 2017 Oct;7(4):515-520. doi: 10.3892/mco.2017.1356. Epub 2017 Jul 31.
6
The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.细胞对血管内皮生长因子的反应需要协调的信号转导、运输和蛋白水解作用。
Biosci Rep. 2015 Aug 18;35(5):e00253. doi: 10.1042/BSR20150171.
7
Novel aspects of corneal angiogenic and lymphangiogenic privilege.角膜血管生成和淋巴管生成特权的新方面。
Prog Retin Eye Res. 2010 May;29(3):208-48. doi: 10.1016/j.preteyeres.2010.01.002. Epub 2010 Jan 25.
8
Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.使用可溶性血管内皮生长因子受体-1、-2和-3进行抗血管生成基因治疗可减少人卵巢实体癌在小鼠体内的生长。
Mol Ther. 2009 Feb;17(2):278-84. doi: 10.1038/mt.2008.258. Epub 2008 Dec 2.
9
The role of VEGF receptors in angiogenesis; complex partnerships.血管内皮生长因子受体在血管生成中的作用;复杂的伙伴关系。
Cell Mol Life Sci. 2006 Mar;63(5):601-15. doi: 10.1007/s00018-005-5426-3.
10
Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.调节人细胞滋养层细胞存活的血管内皮生长因子配体和受体在重度子痫前期及溶血、肝酶升高和血小板减少综合征中表达失调。
Am J Pathol. 2002 Apr;160(4):1405-23. doi: 10.1016/S0002-9440(10)62567-9.